Recent Updates
Recently added Catalysts
FENC Positive Sentiment Score: 70/100

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Thursday, September 5, 2024 2 min read
Key Takeaway: Fennec Pharmaceuticals announced its participation in two upcoming investor conferences, aiming to enhance engagement with investors. The company will present at the H.C. Wainwright Global Investment Conference on September 11, 2024, and at the Cantor Fitzgerald Global Healthcare Conference on September 19, 2024. Additionally, one-on-one investor meetings will be hosted by the management team during these events to bolster investor relations. Fennec is known for its specialty drug, PEDMARK, designed to mitigate platinum-induced ototoxicity in pediatric patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fennec Pharmaceuticals is engaging with investors through upcoming conferences.
  • The management team will host one-on-one investor meetings, enhancing communication.
  • The company's focus on PEDMARK highlights their commitment to pediatric patients.

Full Press Release Details

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences.
Event: H.C. Wainwright Global Investment Conference
Date: September 11, 2024
Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ET
Location: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor
Event: Cantor Fitzgerald Global Healthcare Conference
Date: September 19, 2024
Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ET
Location: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1
For additional information, please visit the investor relations section of the Company’s website at:
https://investors.fennecpharma.com/events-and-presentations/events.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Elixir Health Public Relations
lrocco@elixirhealthpr.com

Frequently Asked Questions

What upcoming conferences will Fennec Pharmaceuticals attend?

Fennec Pharmaceuticals will attend the H.C. Wainwright Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference.

When is Fennec's presentation at the H.C. Wainwright Conference?

The presentation is on September 11, 2024, from 12:00 p.m. to 12:30 p.m. ET.

What is PEDMARK® used for?

PEDMARK® is designed to reduce the risk of platinum-induced ototoxicity in pediatric patients.

When did PEDMARK receive FDA approval?

PEDMARK received FDA approval in September 2022.

Where can I find more information about Fennec Pharmaceuticals?

More information is available on Fennec Pharmaceuticals' investor relations website.

Tags: FENC Viatris Investor Conferences Healthcare PEDMARK pediatric patients investor relations healthcare conferences
Last updated: Sep 5, 2024